Quick Links
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
News
- All
- BMAC updates
- Press Release
- All
- BMAC updates
- Press Release
Takeda opens its first platinum positive energy building in Singapore
First Positive Energy Building in Takeda’s Global Manufacturing Network and Singapore’s Pharmaceutical Industry
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
SINGAPORE – Leading pharma companies GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research (A*STAR); National University ...
GSK opens first-in-Singapore high potency manufacturing and testing facility for next generation cancer treatments | Singapore EDB
GSK plc today announced the opening of a new, S$44 million high potency facility (HPF) in its strategic New Product Introduction site in Jurong, Singapore. ...
Seniors can self-administer the screening of dementia or MCI using artificial intelligence
Seniors in Singapore can use an artificial intelligence-based technology to self-administer the screening of dementia or mild cognitive impairment. Based on their test results, general ...
MSD launches new manufacturing facilities in Singapore for innovative medicines and vaccines as part of up to US$500 million multiyear investment | Singapore EDB
Newly commissioned secondary packaging and sterile filling facility will increase production of immunotherapy for cancer patients in Singapore and the Asia Pacific region.
Sanofi breaks ground on first-of-its-kind Evolutive Vaccine Facility in Asia
The Evolutive Vaccine Facility (EVF) – a “factory of the future” – brings advanced digital and modular vaccine production capabilities to the Asia region
Sanofi breaks ground on first-of-its-kind Evolutive Vaccine Facility in Asia | Singapore EDB
The Evolutive Vaccine Facility (EVF) – a “factory of the future” – brings advanced digital and modular vaccine production capabilities to the Asia region